GlassScriptPhysician profile
Ahmed Baig
NPI 1871933234
$1,326.21
in general payments reported to CMS, 2019-2025
13 companies · $534 in 2025
The $534 reported for 2025 was more than what 80% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $213 · 2022: $195 · 2023: $84.00 · 2024: $301 · 2025: $534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $919.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $918.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $289.00 | 2022-2025 | Auvelity, Sunosi |
| Vanda Pharmaceuticals INC. | $276.53 | 2025 | Fanapt |
| Neos Therapeutics, LP | $152.04 | 2021-2024 | Adzenys Xr-Odt |
| Abbvie INC. | $122.78 | 2025 | |
| Supernus Pharmaceuticals, INC. | $120.79 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $71.61 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Almatica Pharma LLC | $70.88 | 2021-2022 | |
| Corium, LLC | $54.21 | 2023 | Azstarys |
| Luye Pharma (USA) LTD. | $46.29 | 2025 | Erzofri Extended-Release |
| Neurocrine Biosciences, INC. | $38.58 | 2024 | Ingrezza |
| Sage Therapeutics, LLC | $35.00 | 2024 | |
| Idorsia Pharmaceuticals US INC | $29.79 | 2023 | Quviviq |
| Indivior INC. | $18.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmed Baig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.